After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Measuring insulin resistance with a simple, low-cost blood test can help predict the pace of cognitive decline in patients ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

Insulin resistance detected by routine triglyceride-glucose (TyG) index can flag people with early Alzheimer's who are four ...

Arlington Heights, Illinois Thursday, June 26, 2025, 13:00 Hrs [IST] ...

A simple blood test could reveal which early Alzheimer’s patients are most at risk for rapid decline. Researchers found that ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...